Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ola Landgren

Showing results (231-240 of 519) with videos related to

Pageof 52
Sort By:
International Journal of Cancer|November 30, 2006
Risk of second malignant neoplasms among lymphoma patients with a family history of cancerOla Landgren, Ruth M Pfeiffer, Laveta Stewart, et al.
Hepatology (Baltimore, Md.)|December 17, 2008
Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veteransHashem B El-Serag, Eric A Engels, Ola Landgren, et al.
International Journal of Hematology|March 12, 2015
Hodgkin lymphoma risk following infectious and chronic inflammatory diseases: a large population-based case-control study from SwedenSigurdur Y Kristinsson, Ying Gao, Magnus Björkholm, et al.
Annals of Hematology|March 16, 2016
Bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal single-center studyChristian Kjellander, Magnus Björkholm, Owe Källman, et al.
Leukemia|January 23, 2021
Positive selection as the unifying force for clonal evolution in multiple myelomaBenjamin Diamond, Venkata Yellapantula, Even H Rustad, et al.
Cancer Causes & Control : CCC|July 1, 2009
Timing of births and endometrial cancer risk in Swedish womenRuth M Pfeiffer, Aya Mitani, Ola Landgren, et al.
Blood|March 11, 2006
Patterns of autoimmunity and subsequent chronic lymphocytic leukemia in Nordic countriesOla Landgren, Eric A Engels, Neil E Caporaso, et al.
Blood Cancer Discovery|January 4, 2024
Emerging Strategies for the Prevention of Immune Toxicities Associated with T cell-Engaging Cancer TherapiesAndrew Kowalski, Jill Lykon, Benjamin Diamond, et al.
Cancer Chemotherapy and Pharmacology|May 11, 2017
Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphismsTristan M Sissung, Cody J Peer, Neha Korde, et al.
Blood Cancer Journal|April 2, 2022
Body mass index and risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma: Results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening TrialVicky C Chang, Ali A Khan, Wen-Yi Huang, et al.
Pageof 52

Showing results (231-240 of 519) with videos related to

Sort By:
Pageof 52
International Journal of Cancer|November 30, 2006
Risk of second malignant neoplasms among lymphoma patients with a family history of cancerOla Landgren, Ruth M Pfeiffer, Laveta Stewart, et al.
Hepatology (Baltimore, Md.)|December 17, 2008
Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veteransHashem B El-Serag, Eric A Engels, Ola Landgren, et al.
International Journal of Hematology|March 12, 2015
Hodgkin lymphoma risk following infectious and chronic inflammatory diseases: a large population-based case-control study from SwedenSigurdur Y Kristinsson, Ying Gao, Magnus Björkholm, et al.
Annals of Hematology|March 16, 2016
Bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal single-center studyChristian Kjellander, Magnus Björkholm, Owe Källman, et al.
Leukemia|January 23, 2021
Positive selection as the unifying force for clonal evolution in multiple myelomaBenjamin Diamond, Venkata Yellapantula, Even H Rustad, et al.
Cancer Causes & Control : CCC|July 1, 2009
Timing of births and endometrial cancer risk in Swedish womenRuth M Pfeiffer, Aya Mitani, Ola Landgren, et al.
Blood|March 11, 2006
Patterns of autoimmunity and subsequent chronic lymphocytic leukemia in Nordic countriesOla Landgren, Eric A Engels, Neil E Caporaso, et al.
Blood Cancer Discovery|January 4, 2024
Emerging Strategies for the Prevention of Immune Toxicities Associated with T cell-Engaging Cancer TherapiesAndrew Kowalski, Jill Lykon, Benjamin Diamond, et al.
Cancer Chemotherapy and Pharmacology|May 11, 2017
Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphismsTristan M Sissung, Cody J Peer, Neha Korde, et al.
Blood Cancer Journal|April 2, 2022
Body mass index and risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma: Results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening TrialVicky C Chang, Ali A Khan, Wen-Yi Huang, et al.
Pageof 52